Minjung Reger
Primary Care · Doylestown, PANPI 1659813632
Payments from drug & device makers
Across 494 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$865
- LEO Pharma Inc.$676
- Sun Pharmaceutical Industries Inc.$652
- Sanofi$632
- plus $4K from 29 others
What the payments were for
- Food & beverage$8,92098%
- Education$1942%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 71 | $1,282 |
| AbbVie | 75 | $1,033 |
| Regeneron Healthcare Solutions, Inc. | 28 | $865 |
| LEO Pharma Inc. | 52 | $676 |
| Sun Pharmaceutical Industries Inc. | 32 | $652 |
| Sanofi | 24 | $632 |
| Lilly USA, LLC | 28 | $496 |
| Pfizer | 29 | $392 |
| Incyte Corporation | 15 | $354 |
| Novartis | 13 | $261 |
| Galderma Laboratories, L.p. | 16 | $254 |
| E.r. Squibb & Sons, L.L.C. | 9 | $198 |
| Dermavant Sciences, Inc. | 9 | $185 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $151 |
| VYNE Pharmaceuticals Inc. | 11 | $149 |
| Organon | 9 | $141 |
| UCB, Inc. | 4 | $129 |
| Amgen | 5 | $127 |
| Genentech USA, Inc. | 6 | $116 |
| Mayne Pharma Commercial LLC | 4 | $107 |
| Arcutis Biotherapeutics, Inc. | 5 | $105 |
| Kyowa Kirin, Inc. | 5 | $103 |
| Almirall LLC | 5 | $95 |
| Helsinn Therapeutics (U.S.), Inc. | 6 | $82 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Journey Medical Corporation | 4 | $80 |
| EPI Health, LLC | 4 | $77 |
| Biofrontera Inc. | 4 | $69 |
| Boehringer Ingelheim | 3 | $51 |
| Organogenesis Inc. | 2 | $50 |
| Verrica Pharmaceuticals Inc. | 2 | $35 |
| Botanix SB Inc | 1 | $26 |
| Dermira, Inc. | 1 | $25 |
| Merck | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $12 |
How this compares
$9,114 in reported general payments places this provider in the 95th percentile of 300 primary care providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 12 | $43,922 |
| Azelaic Acid | 27 | $1,786 |
| Betamethasone Dipropionate | 56 | $1,557 |
| Fluorouracil | 14 | $1,188 |
| Ketoconazole | 68 | $1,151 |
| Clobetasol Propionate | 39 | $1,062 |
| Tacrolimus | 29 | $1,031 |
| Imiquimod | 26 | $972 |
| Mometasone Furoate | 38 | $734 |
| Gentamicin Sulfate | 21 | $732 |
| Metronidazole | 15 | $716 |
| Finasteride | 17 | $534 |
| Clindamycin Phosphate | 22 | $501 |
| Tretinoin | 16 | $490 |
| Spironolactone | 17 | $292 |
Paid to pharmacies, not to this prescriber.
Other primary care in Doylestown
- Kersten ReiderMount Penn$121K
- Teresa GiamboyPhiladelphia$21K
- Nicole IlgenfritzBethel Park$18K
- Galyna VorokhibPhiladelphia$12K
- Melissa BeansWarrington$12K
- Mollie McGuireJohnstown$11K
- Andrea MauriceNew Cumberland$11K
- Kendell SoglieroSmithfield$9K
- Mackenzie HouserMedia$7K
- Kaylee BakerPhiladelphia$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.